The negotiations list is here; Amgen, Horizon clear FTC hurdle; Fall biotech IPOs?; Novo buys biotech partner in obesity; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

If you get the End­points Week­ly in your email in­box, you may no­tice that we have a new look. Be­tween the se­lec­tion of drugs to go un­der Medicare price ne­go­ti­a­tions and the FTC’s set­tle­ment with Am­gen and Hori­zon, it has been a his­tor­i­cal week with sweep­ing im­pli­ca­tions for bio­phar­ma. And there’s a lot more — see if you missed any ma­jor news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.